56 research outputs found
Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL - An Alternative Approach to Conventional Rational Drug Design
In this study we have calculated a 3D structure of apoptin and through modeling and docking approaches, we show its
interaction with Bcr-Abl oncoprotein and its downstream signaling components, following which we confirm some of the
newly-found interactions by biochemical methods. Bcr-Abl oncoprotein is aberrantly expressed in chronic myelogenous
leukaemia (CML). It has several distinct functional domains in addition to the Abl kinase domain. The SH3 and SH2 domains
cooperatively play important roles in autoinhibiting its kinase activity. Adapter molecules such as Grb2 and CrkL interact
with proline-rich region and activate multiple Bcr-Abl downstream signaling pathways that contribute to growth and
survival. Therefore, the oncogenic effect of Bcr-Abl could be inhibited by the interaction of small molecules with these
domains. Apoptin is a viral protein with well-documented cancer-selective cytotoxicity. Apoptin attributes such as SH2-like
sequence similarity with CrkL SH2 domain, unique SH3 domain binding sequence, presence of proline-rich segments, and
its nuclear affinity render the molecule capable of interaction with Bcr-Abl. Despite almost two decades of research, the
mode of apoptin’s action remains elusive because 3D structure of apoptin is unavailable. We performed in silico threedimensional
modeling of apoptin, molecular docking experiments between apoptin model and the known structure of Bcr-
Abl, and the 3D structures of SH2 domains of CrkL and Bcr-Abl. We also biochemically validated some of the interactions
that were first predicted in silico. This structure-property relationship of apoptin may help in unlocking its cancer-selective
toxic properties. Moreover, such models will guide us in developing of a new class of potent apoptin-like molecules with
greater selectivity and potency
Application of chitosan and its derivatives in Cu(II) ion removal from water used in textile wet processing
Effect of dilatation of peptic esophageal strictures on gastroesophageal reflux, dysphagia, and stricture diameter
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Aberrant activation of oncogenes or loss of tumour suppressor genes opposes malignant transformation by triggering a stable arrest in cell growth, which is termed cellular senescence. This process is finely tuned by both cell-autonomous and non-cell-autonomous mechanisms that regulate the entry of tumour cells to senescence. Whether tumour-infiltrating immune cells can oppose senescence is unknown. Here we show that at the onset of senescence, PTEN null prostate tumours in mice are massively infiltrated by a population of CD11b(+)Gr-1(+) myeloid cells that protect a fraction of proliferating tumour cells from senescence, thus sustaining tumour growth. Mechanistically, we found that Gr-1(+) cells antagonize senescence in a paracrine manner by interfering with the senescence-associated secretory phenotype of the tumour through the secretion of interleukin-1 receptor antagonist (IL-1RA). Strikingly, Pten-loss-induced cellular senescence was enhanced in vivo when Il1ra knockout myeloid cells were adoptively transferred to PTEN null mice. Therapeutically, docetaxel-induced senescence and efficacy were higher in PTEN null tumours when the percentage of tumour-infiltrating CD11b(+)Gr-1(+) myeloid cells was reduced using an antagonist of CXC chemokine receptor 2 (CXCR2). Taken together, our findings identify a novel non-cell-autonomous network, established by innate immunity, that controls senescence evasion and chemoresistance. Targeting this network provides novel opportunities for cancer therapy
A unified nomenclature and amino acid numbering for human PTEN.
The tumor suppressor PTEN is a major brake for cell transformation, mainly due to its phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] phosphatase activity that directly counteracts the oncogenicity of phosphoinositide 3-kinase (PI3K). PTEN mutations are frequent in tumors and in the germ line of patients with tumor predisposition or with neurological or cognitive disorders, which makes the PTEN gene and protein a major focus of interest in current biomedical research. After almost two decades of intense investigation on the 403-residue-long PTEN protein, a previously uncharacterized form of PTEN has been discovered that contains 173 amino-terminal extra amino acids, as a result of an alternate translation initiation site. To facilitate research in the field and to avoid ambiguities in the naming and identification of PTEN amino acids from publications and databases, we propose here a unifying nomenclature and amino acid numbering for this longer form of PTEN
- …